Transferring type 2 diabetes patients with uncontrolled glycaemia from biphasic human insulin to biphasic insulin aspart 30: Experiences from the PRESENT study

Current Medical Research and Opinion

Volumn 23, Issue 12, 2007, Pages 3209-3214

  Shestakova, M ^a,j   Sharma, S K ^b   Almustafa, M ^c   Min, K W ^d   Ayad, N ^e   Azar, S T ^f   Danciulescu, R ^g   Khutsoane, D ^h   Guler, S ⁱ  

^a Institute of Diabetes   (Russian Federation)

^b MG Medical College Jaipur   (India)

^c UNIVERSITY OF BAGHDAD   (Iraq)

^d Eulji General Hospital   (South Korea)

^e Taiba Hospital   (Kuwait)

^f AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^g Nutrition and Metabolic Diseases 'N Paulescu'   (Romania)

^h Bloemfontein Medi Clinic   (South Africa)

ⁱ ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^j ENDOCRINOLOGY RESEARCH CENTRE   (Russian Federation)

more..

Author keywords

Biphasic human insulin; Biphasic insulin aspart 30; HbA1c; Hypoglycaemia; Type 2 diabetes mellitus

Indexed keywords

ANTIDIABETIC AGENT; BIPHASIC INSULIN; HEMOGLOBIN A1C; INSULIN ASPART;

ADULT; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE BRAIN LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORBIDITY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; POSTPRANDIAL STATE; PROSPECTIVE STUDY; SIDE EFFECT; STUDENT T TEST;

EID: 37749014620     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X253636     Document Type: Article

References (22)

1. IDF Clinical Guidelines Task Force. Global Guideline for type 2 diabetes. Brussels: International Diabetes Federation, 2005
2. Garber AJ, Wahlen J, Wahl T, et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Diabetes Obes Metab 2006;8:58-66
3. Ligtfielm RJ, Mouritzen U, Lynggaard H, et al. Biphasic insulin aspart given thrice daily is as efficacious as a basal-bolus insulin regimen with four daily injections. Exp Clin Endocrinol Diabetes 2006;114:511-19
4. 1c target < 7.0%. Diabetologia 2006; 49 (Suppl 1):610-11
5. Bolli GB, Di Marchi RD, Park GB, et al. Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia 1999;42:1151-67
6. Brange J, Volund A. Insulin analogs with improved pharmacokinetic profiles. Adv Drug Deliv Rev 1999;35:307-35
7. Heinemann L. Do insulin-treated diabetic patients use an injection-meal-interval in daily life? Diabet Med 1995;12:449-50
8. Overmann H, Heinemann L. Injection-meal interval: recommendations of diabetologists and how patients handle it. Diabetes Res Clin Pract 1999;43:137-42
9. Jacobsen LV, Sogaard B, Riis A. Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart. Eur J Clin Pharmacol 2000;56:399-403
10. McSorley, Bell PM, Jacobsen LV, et al. Twice-daily biphasic insulin aspart 30 versus biphasic human insulin 30: a double-blind crossover study in adults with type 2 diabetes mellitus. Clin Ther 2002;24:530-9
11. McNally PG, Dean JD, Morris AD, et al. Using continuous glucose monitoring to measure the frequency of low glucose values when using biphasic insulin aspart 30 compared with biphasic human insulin 30: a double-blind crossover study in individuals with type 2 diabetes. Diabetes Care 2007;30:1044-8
12. Rizvi AA, Ligthelm RJ. The use of premixed insulin analogues in the treatment of patients with type 2 diabetes mellitus: advantages and limitations. Insulin 2007;2:68-79
13. Boehm BO, Home PD, Kamp BNM, Lindholm A. Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in type 1 and type 2 diabetic patients. Diabet Med 2002;19:393-9
14. Boehm BO, Vaz JA, Brondsted L, Home PD. Long-term efficacy and safety of biphasic insulin aspart in patients with type 2 diabetes. Eur J Inter Med 2004;15:496-502
15. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2004;27(Suppl 1):S15-35
16. Abrahamian H, Ludvik B, Schernthaner G, et al. Improvement of glucose tolerance in type 2 diabetic patients: traditional vs. modern insulin regimens (Results from the Austrian Biaspart study). Horm Metab Res 2005;37:684-9
17. Schwartz S, Sievers R, Strange P, et al., for the INS-2061 study team. Insulin 70/30 mix plus metformin versus triple oral therapy in the treatment of type 2 diabetes after failure of two oral drugs: Efficacy, safety, and cost analysis. Diabetes Care 2003;26:2238-43
18. Raskin PR, Hollander PA, Lewin A, et al., on behalf of the INITIATE study group. Basal insulin or premix analogue therapy in type 2 diabetes patients. Eur J Intern Med 2007;18: 56-62
19. Raskin P, Allen E, Hollander P, et al., for the INITIATE study group. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analog. Diabetes Care 2005;28:260-5
20. Davidson J, Vexiau P, Cucinotta D, et al. Biphasic insulin aspart 30: literature review of adverse events associated with treatment. Clin Ther 2005;27(Suppl B):S75-88
21. Raz I, Mouritzen U, Vaz J, et al. Addition of biphasic insulin aspart 30 to rosiglitazone in type 2 diabetes mellitus that is poorly controlled with glibenclamide monotherapy. Clin Ther 2003;25:3109-23
22. Ligthelm RJ, Borzi V, Gumprecht J, et al. Importance of observational studies in clinical practice. Clin Ther 2007;29:1284-92